Patents by Inventor David E. Seyler

David E. Seyler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for inhibiting endometriosis
    Patent number: 5693656
    Abstract: A method of inhibiting endometriosis comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: December 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Larry J. Black, George J. Cullinan, Michael W. Draper, Charles D. Jones, David E. Seyler
  • Methods for inhibiting endometriosis
    Patent number: 5461065
    Abstract: A method of inhibiting endometriosis comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: October 24, 1995
    Assignee: Eli Lilly and Company
    Inventors: Larry J. Black, George J. Cullinan, Michael W. Draper, Charles D. Jones, David E. Seyler
  • Methods of inhibiting uterine fibrosis
    Patent number: 5457116
    Abstract: A method of inhibiting uterine fibrosis comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; wherein R.sup.2 is selected from the group consisting of pyrrolidino and piperidino, a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: Larry J. Black, George J. Cullinan, Michael W. Draper, Charles D. Jones, David E. Seyler